Conditions: Chronic Hepatitis C
Keywords: Ravidasvir HCV GT1 SVR12 Danoprevir/r
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 38
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the efficacy, safety and tolerability of Ravidasvir (ASC16) in combination with Ritonavir-boosted Danoprevir(ASC08) and Ribavirin in treatment-naive no-cirrhotic Taiwanese patients who have chronic hepatitis C genotype1.

Detailed description:

Arms:
arm 1: Participants will receive Ravidasvir 200mg plus Ritonavir boosted Danoprevir 200/200mg,and Ribavirin 1000/1200mg daily for 12 weeks.

Interventions: intervention 1: Ravidasvir intervention 2: Danoprevir intervention 3: Ritonavir intervention 4: Ribavirin
Intervention descriptions: intervention 1: Ravidasvir 200mg tablet administered orally once daily intervention 2: Danoprevir 100mg tablet administered orally twice daily intervention 3: Ritonavir 100mg tablet administered orally twice daily intervention 4: Ribavirin(RBV)1000/1200 mg/day (bodyweight\<75/≥75 kg)administered orally

Protocol document: